Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump in ...
PA Media on MSN2h
Novo Nordisk reprimanded for allegedly failing to disclose paymentsThe manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...
Novo Nordisk A/S Bagsværd, Denmark, 4 February 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the ...
BAGSVAERD, Denmark — BAGSVAERD, Denmark — Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter earnings of $4.04 billion. The Bagsvaerd, Denmark-based company said it had net income of ...
Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC ...
Novo Nordisk’s annual results are out and they ... The Copenhagen-based company’s revenue was equal to 10% of Denmark’s GDP last year. They turned that DKK 290 billion in revenue into ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results